Imagine having a camera that can zoom from a wide view of a whole city down to a single grain of sand on a sidewalk, all in one shot. This technology does that for human tissue, letting scientists see the big picture of a tumor and then dive deep into the tiniest molecular details. It uses special light-modulating chips to make this process much faster and more accurate than current tools.
Current spatial biology tools lack a single instrument capable of covering the full scale from tissue (mm) to molecule (nm) with high speed and accuracy, hindering personalized cancer therapy.
A multi-scale 3D imaging platform (SAFe-nSCAN) and a multi-color high-power interchangeable laser-compatible chip.
If you are a drug developer dealing with imprecise cellular targeting in cancer treatments — this project developed the SAFe-nSCAN platform that provides 3D spatial biology insights for personalized immune-oncology therapy.
If you are a manufacturer dealing with the need for high-precision light control in microscopy — this project developed a multi-color high-power interchangeable laser-compatible chip to increase imaging speed and efficiency.
If you are a lab dealing with the limitation of wide-field microscopy that lacks molecular profiling — this project developed a tool covering the entire length spectrum from mm to nm in a single instrument.
Based on available project data, specific pricing or cost details are not provided.
Yes, the consortium includes an SME collaborating with a new startup specifically to manufacture the chips and bring the technology to the spatial biology market.
Based on available project data, the platform integrates innovative technologies owned by different consortium members, but specific licensing terms are not listed.
The platform replaces the need for multiple instruments by combining wide-field, structured illumination, and single-molecule localization microscopy into one device.
The project period runs from 2023-10-01 to 2026-09-30, suggesting a transition toward market readiness by late 2026.
The consortium is heavily research-driven with 3 research organizations and 1 university, but it has a clear commercialization path. With an industry ratio of 17% and the inclusion of an SME and a dedicated startup for chip manufacturing, the project is structured to move academic breakthroughs into a commercial product.
Contact CNRS (France) regarding the SAFe-nSCAN platform development.
Contact us to connect with the NanoSCAN consortium for beta testing opportunities.
